CNS5:Volunteer Assignments and Opportunities: Difference between revisions
| [checked revision] | [checked revision] |
No edit summary |
Author content - pending or complete - column |
||
| (15 intermediate revisions by 2 users not shown) | |||
| Line 6: | Line 6: | ||
To volunteer, please '''[[Mailto:CCGA@cancergenomics.org <u>Contact us</u>]]''' with your page of interest.<br /> | To volunteer, please '''[[Mailto:CCGA@cancergenomics.org <u>Contact us</u>]]''' with your page of interest.<br /> | ||
__TOC__ | |||
{| class="wikitable" style="margin:auto" | {| class="wikitable" style="margin:auto" | ||
|+<big>WHO Classification of Tumours of the Central Nervous System (5th Edition) Content</big> | |+<big>WHO Classification of Tumours of the Central Nervous System (5th Edition) Content</big> | ||
| Line 17: | Line 18: | ||
!'''Notes''' | !'''Notes''' | ||
|- | |- | ||
|CHAPTER 2 (GLIOMAS, GLIONEURONAL TUMOURS, AND NEURONAL TUMOURS) | | | ||
====CHAPTER 2 (GLIOMAS, GLIONEURONAL TUMOURS, AND NEURONAL TUMOURS)==== | |||
| | | | ||
---- | ---- | ||
| Line 42: | Line 44: | ||
|6/25/2023 | |6/25/2023 | ||
| | | | ||
| | |COMPLETE | ||
| | | | ||
|Laveniya Satgunaseelan (LS) | |Laveniya Satgunaseelan (LS) | ||
| Line 61: | Line 63: | ||
|[[CNS5:Glioblastoma,_IDH-wildtype|Glioblastoma, IDH-wildtype]] | |[[CNS5:Glioblastoma,_IDH-wildtype|Glioblastoma, IDH-wildtype]] | ||
|Disease | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | |||
| | |||
| | | | ||
|Moved from "Glioblastoma, IDH-wildtype" to new page; 2021 template added | |Moved from "Glioblastoma, IDH-wildtype" to new page; 2021 template added | ||
| Line 75: | Line 77: | ||
|6/27/2023 | |6/27/2023 | ||
| | | | ||
| | |COMPLETE | ||
| | | | ||
|LS | |LS | ||
| Line 108: | Line 110: | ||
|5/3/2024 | |5/3/2024 | ||
| | | | ||
|PENDING | |PENDING - email reminder 9/4/2025 | ||
| | | | ||
|LS | |LS | ||
| Line 116: | Line 118: | ||
|[[CNS5:Diffuse_midline_glioma,_H3_K27-altered|Diffuse midline glioma, H3 K27-altered]] | |[[CNS5:Diffuse_midline_glioma,_H3_K27-altered|Diffuse midline glioma, H3 K27-altered]] | ||
|Disease | |Disease | ||
|Laveniya Satgunaseelan | |Laveniya Satgunaseelan | ||
| | | | ||
| | | | ||
| Line 135: | Line 137: | ||
| | | | ||
|2021 template added | |2021 template added | ||
|- | |||
!'''Disease''' | |||
!'''Page Type''' | |||
!'''<span style="color:#0070C0">Author''' | |||
!'''Date Assigned to Author''' | |||
!'''Target Completion Date''' | |||
!'''Author Content (Pending or Complete)''' | |||
!'''Date Completed by Author''' | |||
!'''Associate Editor''' | |||
!'''Date of Last Editor Review''' | |||
!'''Notes''' | |||
|- | |- | ||
|[[CNS5:Diffuse_paediatric-type_high-grade_glioma,_H3-wildtype_and_IDH-wildtype|Diffuse paediatric-type high-grade glioma, H3-wildtype and IDH-wildtype]] | |[[CNS5:Diffuse_paediatric-type_high-grade_glioma,_H3-wildtype_and_IDH-wildtype|Diffuse paediatric-type high-grade glioma, H3-wildtype and IDH-wildtype]] | ||
| Line 160: | Line 173: | ||
|[[CNS5:Pilocytic_astrocytoma_|Pilocytic astrocytoma]] | |[[CNS5:Pilocytic_astrocytoma_|Pilocytic astrocytoma]] | ||
|Disease | |Disease | ||
| | | | ||
| | |<br /> | ||
| | |||
| | |||
| | | | ||
|LS | |LS | ||
| Line 182: | Line 195: | ||
|[[CNS5:Pleomorphic_xanthoastrocytoma|Pleomorphic xanthoastrocytoma]] | |[[CNS5:Pleomorphic_xanthoastrocytoma|Pleomorphic xanthoastrocytoma]] | ||
|Disease | |Disease | ||
|Wahab Khan | |||
|15/04/2025 | |||
| | | | ||
| | |PENDING - email reminder 9/4/2025 | ||
| | | | ||
|LS | |LS | ||
| Line 246: | Line 259: | ||
| | | | ||
|- | |- | ||
|[[CNS5:Desmoplastic_infantile_ganglioglioma_/_desmoplastic_infantile_astrocytoma|Desmoplastic infantile ganglioglioma / desmoplastic infantile astrocytoma]] | !'''Disease''' | ||
!'''Page Type''' | |||
!'''<span style="color:#0070C0">Author''' | |||
!'''Date Assigned to Author''' | |||
!'''Target Completion Date''' | |||
!'''Author Content (Pending or Complete)''' | |||
!'''Date Completed by Author''' | |||
!'''Associate Editor''' | |||
!'''Date of Last Editor Review''' | |||
!'''Notes''' | |||
|- | |||
|[[CNS5:Desmoplastic_infantile_ganglioglioma_/_desmoplastic_infantile_astrocytoma|Desmoplastic infantile ganglioglioma / desmoplastic infantile astrocytoma]] | |||
|Disease | |Disease | ||
| | | | ||
| Line 314: | Line 338: | ||
|[[CNS5:Diffuse_leptomeningeal_glioneuronal_tumour|Diffuse leptomeningeal glioneuronal tumour]] | |[[CNS5:Diffuse_leptomeningeal_glioneuronal_tumour|Diffuse leptomeningeal glioneuronal tumour]] | ||
|Disease | |Disease | ||
|Laveniya Satgunaseelan | |||
|9/11/2024 | |||
| | | | ||
| | |COMPLETE | ||
| | |8/7/2025 | ||
| | |LS | ||
| | |LS | ||
| | |Used for testing 9/2024 somatic template | ||
|- | |- | ||
|[[CNS5:Multinodular_and_vacuolating_neuronal_tumour|Multinodular and vacuolating neuronal tumour]] | |[[CNS5:Multinodular_and_vacuolating_neuronal_tumour|Multinodular and vacuolating neuronal tumour]] | ||
| Line 355: | Line 379: | ||
| | | | ||
| | | | ||
|- | |||
!'''Disease''' | |||
!'''Page Type''' | |||
!'''<span style="color:#0070C0">Author''' | |||
!'''Date Assigned to Author''' | |||
!'''Target Completion Date''' | |||
!'''Author Content (Pending or Complete)''' | |||
!'''Date Completed by Author''' | |||
!'''Associate Editor''' | |||
!'''Date of Last Editor Review''' | |||
!'''Notes''' | |||
|- | |- | ||
|[[CNS5:Extraventricular_neurocytoma|Extraventricular neurocytoma]] | |[[CNS5:Extraventricular_neurocytoma|Extraventricular neurocytoma]] | ||
| Line 465: | Line 500: | ||
| | | | ||
| | | | ||
|- | |||
!'''Disease''' | |||
!'''Page Type''' | |||
!'''<span style="color:#0070C0">Author''' | |||
!'''Date Assigned to Author''' | |||
!'''Target Completion Date''' | |||
!'''Author Content (Pending or Complete)''' | |||
!'''Date Completed by Author''' | |||
!'''Associate Editor''' | |||
!'''Date of Last Editor Review''' | |||
!'''Notes''' | |||
|- | |- | ||
|[[CNS5:Myxopapillary_ependymoma|Myxopapillary ependymoma]] | |[[CNS5:Myxopapillary_ependymoma|Myxopapillary ependymoma]] | ||
| Line 488: | Line 534: | ||
| | | | ||
|- | |- | ||
|CHAPTER 3 (CHOROID PLEXUS TUMOURS) | | | ||
====CHAPTER 3 (CHOROID PLEXUS TUMOURS)==== | |||
| | | | ||
---- | ---- | ||
| Line 541: | Line 588: | ||
| | | | ||
|- | |- | ||
|CHAPTER 4 (EMBRYONAL TUMOURS) | | | ||
====CHAPTER 4 (EMBRYONAL TUMOURS)==== | |||
| | | | ||
---- | ---- | ||
| Line 593: | Line 641: | ||
| | | | ||
| | | | ||
|- | |||
!'''Disease''' | |||
!'''Page Type''' | |||
!'''<span style="color:#0070C0">Author''' | |||
!'''Date Assigned to Author''' | |||
!'''Target Completion Date''' | |||
!'''Author Content (Pending or Complete)''' | |||
!'''Date Completed by Author''' | |||
!'''Associate Editor''' | |||
!'''Date of Last Editor Review''' | |||
!'''Notes''' | |||
|- | |- | ||
|[[CNS5:Medulloblastoma,_non-WNT/non-SHH|Medulloblastoma, non-WNT/non-SHH]] | |[[CNS5:Medulloblastoma,_non-WNT/non-SHH|Medulloblastoma, non-WNT/non-SHH]] | ||
| Line 682: | Line 741: | ||
| | | | ||
|- | |- | ||
|CHAPTER 5 (PINEAL TUMOURS) | | | ||
====CHAPTER 5 (PINEAL TUMOURS)==== | |||
| | | | ||
---- | ---- | ||
| Line 712: | Line 772: | ||
| | | | ||
| | | | ||
|- | |||
!'''Disease''' | |||
!'''Page Type''' | |||
!'''<span style="color:#0070C0">Author''' | |||
!'''Date Assigned to Author''' | |||
!'''Target Completion Date''' | |||
!'''Author Content (Pending or Complete)''' | |||
!'''Date Completed by Author''' | |||
!'''Associate Editor''' | |||
!'''Date of Last Editor Review''' | |||
!'''Notes''' | |||
|- | |- | ||
|[[CNS5:Pineal_parenchymal_tumour_of_intermediate_differentiation|Pineal parenchymal tumour of intermediate differentiation]] | |[[CNS5:Pineal_parenchymal_tumour_of_intermediate_differentiation|Pineal parenchymal tumour of intermediate differentiation]] | ||
| Line 757: | Line 828: | ||
| | | | ||
|- | |- | ||
|CHAPTER 6 (CRANIAL AND PARASPINAL NERVE TUMOURS) | | | ||
====CHAPTER 6 (CRANIAL AND PARASPINAL NERVE TUMOURS)==== | |||
| | | | ||
---- | ---- | ||
| Line 831: | Line 903: | ||
| | | | ||
| | | | ||
|- | |||
!'''Disease''' | |||
!'''Page Type''' | |||
!'''<span style="color:#0070C0">Author''' | |||
!'''Date Assigned to Author''' | |||
!'''Target Completion Date''' | |||
!'''Author Content (Pending or Complete)''' | |||
!'''Date Completed by Author''' | |||
!'''Associate Editor''' | |||
!'''Date of Last Editor Review''' | |||
!'''Notes''' | |||
|- | |- | ||
|[[CNS5:Malignant_peripheral_nerve_sheath_tumour|Malignant peripheral nerve sheath tumour]] | |[[CNS5:Malignant_peripheral_nerve_sheath_tumour|Malignant peripheral nerve sheath tumour]] | ||
| Line 854: | Line 937: | ||
| | | | ||
|- | |- | ||
|CHAPTER 7 (MENINGIOMA) | | | ||
====CHAPTER 7 (MENINGIOMA)==== | |||
| | | | ||
---- | ---- | ||
| Line 885: | Line 969: | ||
| | | | ||
|- | |- | ||
|CHAPTER 8 (MESENCHYMAL, NON-MENINGOTHELIAL TUMOURS INVOLVING THE CNS) | | | ||
====CHAPTER 8 (MESENCHYMAL, NON-MENINGOTHELIAL TUMOURS INVOLVING THE CNS)==== | |||
| | | | ||
---- | ---- | ||
| Line 960: | Line 1,045: | ||
| | | | ||
|- | |- | ||
|[[CNS5:CIC-rearranged_sarcoma|CIC-rearranged sarcoma]] | !'''Disease''' | ||
!'''Page Type''' | |||
!'''<span style="color:#0070C0">Author''' | |||
!'''Date Assigned to Author''' | |||
!'''Target Completion Date''' | |||
!'''Author Content (Pending or Complete)''' | |||
!'''Date Completed by Author''' | |||
!'''Associate Editor''' | |||
!'''Date of Last Editor Review''' | |||
!'''Notes''' | |||
|- | |||
|[[CNS5:CIC-rearranged_sarcoma|CIC-rearranged sarcoma]] | |||
|Disease | |Disease | ||
| | | | ||
| Line 1,026: | Line 1,122: | ||
| | | | ||
|- | |- | ||
|CHAPTER 9 (MELANOCYTIC TUMOURS) | | | ||
====CHAPTER 9 (MELANOCYTIC TUMOURS)==== | |||
| | | | ||
---- | ---- | ||
| Line 1,068: | Line 1,165: | ||
| | | | ||
|- | |- | ||
|CHAPTER 10 (HAEMATOLYMPHOID TUMOURS INVOLVING THE CNS) | | | ||
====CHAPTER 10 (HAEMATOLYMPHOID TUMOURS INVOLVING THE CNS)==== | |||
| | | | ||
---- | ---- | ||
| Line 1,098: | Line 1,196: | ||
| | | | ||
| | | | ||
|- | |||
!'''Disease''' | |||
!'''Page Type''' | |||
!'''<span style="color:#0070C0">Author''' | |||
!'''Date Assigned to Author''' | |||
!'''Target Completion Date''' | |||
!'''Author Content (Pending or Complete)''' | |||
!'''Date Completed by Author''' | |||
!'''Associate Editor''' | |||
!'''Date of Last Editor Review''' | |||
!'''Notes''' | |||
|- | |- | ||
|[[CNS5:Immunodeficiency-associated_CNS_lymphomas|Immunodeficiency-associated CNS lymphomas]] | |[[CNS5:Immunodeficiency-associated_CNS_lymphomas|Immunodeficiency-associated CNS lymphomas]] | ||
| Line 1,208: | Line 1,317: | ||
| | | | ||
| | | | ||
|- | |||
!'''Disease''' | |||
!'''Page Type''' | |||
!'''<span style="color:#0070C0">Author''' | |||
!'''Date Assigned to Author''' | |||
!'''Target Completion Date''' | |||
!'''Author Content (Pending or Complete)''' | |||
!'''Date Completed by Author''' | |||
!'''Associate Editor''' | |||
!'''Date of Last Editor Review''' | |||
!'''Notes''' | |||
|- | |- | ||
|[[CNS5:Langerhans_cell_histiocytosis|Langerhans cell histiocytosis]] | |[[CNS5:Langerhans_cell_histiocytosis|Langerhans cell histiocytosis]] | ||
| Line 1,231: | Line 1,351: | ||
| | | | ||
|- | |- | ||
|CHAPTER 11 (GERM CELL TUMOURS) | | | ||
====CHAPTER 11 (GERM CELL TUMOURS)==== | |||
| | | | ||
---- | ---- | ||
| Line 1,262: | Line 1,383: | ||
| | | | ||
|- | |- | ||
|CHAPTER 12 (TUMOURS OF THE SELLAR REGION | | | ||
====CHAPTER 12 (TUMOURS OF THE SELLAR REGION==== | |||
| | | | ||
---- | ---- | ||
| Line 1,337: | Line 1,459: | ||
| | | | ||
|- | |- | ||
|CHAPTER 13 (METASTASES TO THE CNS) | !'''Disease''' | ||
!'''Page Type''' | |||
!'''<span style="color:#0070C0">Author''' | |||
!'''Date Assigned to Author''' | |||
!'''Target Completion Date''' | |||
!'''Author Content (Pending or Complete)''' | |||
!'''Date Completed by Author''' | |||
!'''Associate Editor''' | |||
!'''Date of Last Editor Review''' | |||
!'''Notes''' | |||
|- | |||
| | |||
====CHAPTER 13 (METASTASES TO THE CNS)==== | |||
| | | | ||
---- | ---- | ||
| Line 1,379: | Line 1,513: | ||
| | | | ||
|- | |- | ||
|CHAPTER 14 (GENETIC TUMOUR SYNDROMES INVOLVING THE CNS) | | | ||
====CHAPTER 14 (GENETIC TUMOUR SYNDROMES INVOLVING THE CNS)==== | |||
| | | | ||
---- | ---- | ||
| Line 1,401: | Line 1,536: | ||
|[[CNS5:Neurofibromatosis_type_1|Neurofibromatosis type 1]] | |[[CNS5:Neurofibromatosis_type_1|Neurofibromatosis type 1]] | ||
|Disease | |Disease | ||
| | |[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
|- | |- | ||
|[[CNS5:Neurofibromatosis_type_2|Neurofibromatosis type 2]] | |[[CNS5:Neurofibromatosis_type_2|Neurofibromatosis type 2]] | ||
|Disease | |Disease | ||
| | |[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
|- | |- | ||
|[[CNS5:Schwannomatosis|Schwannomatosis]] | |[[CNS5:Schwannomatosis|Schwannomatosis]] | ||
|Disease | |Disease | ||
| | | | ||
| | | | ||
| Line 1,434: | Line 1,569: | ||
|[[CNS5:Von_Hippel-Lindau_syndrome|Von Hippel-Lindau syndrome]] | |[[CNS5:Von_Hippel-Lindau_syndrome|Von Hippel-Lindau syndrome]] | ||
|Disease | |Disease | ||
| | |[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
|- | |- | ||
|[[CNS5:Tuberous_sclerosis|Tuberous sclerosis]] | |[[CNS5:Tuberous_sclerosis|Tuberous sclerosis]] | ||
| Line 1,456: | Line 1,591: | ||
|[[CNS5:Li-Fraumeni_syndrome|Li-Fraumeni syndrome]] | |[[CNS5:Li-Fraumeni_syndrome|Li-Fraumeni syndrome]] | ||
|Disease | |Disease | ||
| | |[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
|- | |||
!'''Disease''' | |||
!'''Page Type''' | |||
!'''<span style="color:#0070C0">Author''' | |||
!'''Date Assigned to Author''' | |||
!'''Target Completion Date''' | |||
!'''Author Content (Pending or Complete)''' | |||
!'''Date Completed by Author''' | |||
!'''Associate Editor''' | |||
!'''Date of Last Editor Review''' | |||
!'''Notes''' | |||
|- | |- | ||
|[[CNS5:Cowden_syndrome|Cowden syndrome]] | |[[CNS5:Cowden_syndrome|Cowden syndrome]] | ||
|Disease | |Disease | ||
| | |[[DIG5:Volunteer Assignments and Opportunities|See DIG5 volunteer sheet for authorship status]] | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
|- | |- | ||
|[[CNS5:Constitutional_mismatch_repair_deficiency_syndrome|Constitutional mismatch repair deficiency syndrome]] | |[[CNS5:Constitutional_mismatch_repair_deficiency_syndrome|Constitutional mismatch repair deficiency syndrome]] | ||
|Disease | |Disease | ||
| | |[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
|- | |- | ||
|[[CNS5:Familial_adenomatous_polyposis_1|Familial adenomatous polyposis 1]] | |[[CNS5:Familial_adenomatous_polyposis_1|Familial adenomatous polyposis 1]] | ||
| Line 1,533: | Line 1,679: | ||
|[[CNS5:DICER1_syndrome|DICER1 syndrome]] | |[[CNS5:DICER1_syndrome|DICER1 syndrome]] | ||
|Disease | |Disease | ||
| | |[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
|- | |- | ||
|[[CNS5:Familial_paraganglioma_syndromes|Familial paraganglioma syndromes]] | |[[CNS5:Familial_paraganglioma_syndromes|Familial paraganglioma syndromes]] | ||
| Line 1,574: | Line 1,720: | ||
| | | | ||
| | | | ||
|- | |||
!'''Disease''' | |||
!'''Page Type''' | |||
!'''<span style="color:#0070C0">Author''' | |||
!'''Date Assigned to Author''' | |||
!'''Target Completion Date''' | |||
!'''Author Content (Pending or Complete)''' | |||
!'''Date Completed by Author''' | |||
!'''Associate Editor''' | |||
!'''Date of Last Editor Review''' | |||
!'''Notes''' | |||
|- | |- | ||
|[[CNS5:BAP1_tumour_predisposition_syndrome|BAP1 tumour predisposition syndrome]] | |[[CNS5:BAP1_tumour_predisposition_syndrome|BAP1 tumour predisposition syndrome]] | ||
| Line 1,588: | Line 1,745: | ||
|[[CNS5:Fanconi_anaemia|Fanconi anaemia]] | |[[CNS5:Fanconi_anaemia|Fanconi anaemia]] | ||
|Disease | |Disease | ||
| | |[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
| | |N/A | ||
|- | |- | ||
|[[CNS5:ELP1-medulloblastoma_syndrome|ELP1-medulloblastoma syndrome]] | |[[CNS5:ELP1-medulloblastoma_syndrome|ELP1-medulloblastoma syndrome]] | ||